Glutathione

Overview

Glutathione (GSH) is an endogenous tripeptide made of three amino acids — glutamate, cysteine, and glycine — joined as gamma-L-glutamyl-L-cysteinyl-glycine. It is the body's principal intracellular antioxidant and one of the most important redox buffers in nearly every human cell.

Unlike several other molecules cataloged on this site alongside peptides — methylene blue (a redox dye) or NAD+ (a coenzyme), for example — glutathione genuinely is a peptide. It is a small, naturally occurring thiol tripeptide, not a synthetic drug. The reason it belongs in a peptide reference at all is that it is endogenous, peptide-structured, and frequently discussed and stacked WITH peptides in the longevity and "recovery" community.

Two structural details define its behavior. First, the bond between glutamate and cysteine is an unusual gamma-peptide bond, which makes glutathione resistant to standard peptidases — most enzymes that chew up peptides cannot cleave it. Second, the free cysteine thiol (-SH) group is the reactive center: it is what donates electrons, scavenges radicals, and conjugates toxins.

Glutathione is sold as oral capsules/tablets, liposomal and micellar oral formulations, and IV/injectable solutions, and is heavily marketed for "detox," immune support, liver conditions, and cosmetic skin-lightening. The evidence for these uses is mixed and mostly supplement-grade: oral supplementation can raise body glutathione stores, but proof that this translates into hard clinical disease outcomes is largely lacking, and the injectable/cosmetic uses carry real safety concerns.

Chemistry and structure

The molecule exists in two interconverting states: reduced (GSH) and oxidized (GSSG), in which two glutathione molecules are joined by a disulfide bond. The GSH/GSSG ratio is a core cellular redox marker — a high ratio signals a well-buffered, reducing environment.

Mechanism of action

Glutathione's actions are enzyme-cofactor and redox-chemistry based, not receptor-mediated. The core mechanisms are well established in human biochemistry; the therapeutic claims built on top of them are far less certain.

1. Cofactor for glutathione peroxidases. GSH donates electrons to reduce hydrogen peroxide and lipid hydroperoxides to water/alcohols, becoming oxidized to GSSG in the process. Glutathione reductase (NADPH-dependent) then regenerates GSH from GSSG. This is a core enzymatic antioxidant defense. [Human/Biochemistry]

2. Nucleophilic co-substrate for glutathione S-transferases (Phase II detox). The free cysteine thiol acts as a nucleophile, conjugating glutathione to electrophilic xenobiotics and toxins so they can be excreted. This is the biochemical basis for the "detox" framing (though the marketing usually overstates it). [Human/Biochemistry]

3. Direct radical scavenging and vitamin recycling. GSH can directly quench free radicals and help regenerate oxidized vitamins C and E, a non-enzymatic antioxidant recycling loop. [In vitro/Biochemistry]

4. Master redox buffer. The GSH/GSSG couple buffers cellular redox state and thereby influences signaling and apoptosis. This is a redox-couple effect, not a specific receptor action. [Human/Biochemistry]

5. Melanogenesis modulation (skin-lightening hypothesis). GSH is proposed to inhibit tyrosinase and shift pigment synthesis from darker eumelanin toward lighter pheomelanin — the mechanistic rationale cited for skin-lightening claims. The mechanism is cited in the dermatology literature, but injectable clinical efficacy for lightening is not established and is FDA-warned. [Hypothesis/In vitro]

Research and evidence

The honest summary: glutathione's biochemistry is well established, oral supplementation can raise body stores, but disease-outcome efficacy in humans remains largely unproven, and the strongest safety signals concern injectable/cosmetic use.

What the human data actually support. The best single human study is the Richie 2015 RCT: over six months, daily oral glutathione raised body glutathione stores and lowered the oxidized-to-reduced ratio, with a secondary immune signal (higher NK-cell cytotoxicity). That is a genuine, well-designed result — but it measures body stores and surrogate markers, not hard clinical endpoints, and the effect reversed after a washout. Oral bioavailability of standard GSH is historically poor because it is degraded in the GI tract; newer liposomal/micellar formulations report higher blood exposure in small crossover trials, but head-to-head, outcome-based comparisons are lacking. An RCT in elderly type 2 diabetics (500 mg/day oral GSH, 6 months) reported reduced oxidative DNA damage and lower HbA1c, which is encouraging but preliminary. Overall, the leap from "raises glutathione levels" to "treats disease" is not supported by robust human outcome trials.

Status and regulation

• Oral (US): sold as a dietary supplement under DSHEA. Effects are not evaluated by the FDA, and no disease-treatment claims are approved.
• Injectable/IV (US): not FDA-approved. There is no FDA-approved injectable glutathione, and no approved injectable skin-lightening product of any kind. In February 2019 the FDA warned compounders against a specific glutathione powder (Letco Medical) after endotoxin-related adverse events.
• Abroad: injectable glutathione is reportedly registered as a medicine in some countries (e.g. branded "Tationil" in Italy). This was not independently verified with a primary regulatory source in this session and is flagged as unknown, not asserted.
• WADA: glutathione is not a prohibited substance. However, intravenous infusions of more than 100 mL per 12-hour period are banned as a prohibited method (M2), regardless of what is infused. There is no applicable WADA class code because it is not a prohibited substance.

Regulatory status is jurisdiction-specific and can change. This page is not legal advice.

Safety

For oral use, glutathione is generally regarded as well tolerated at supplement doses, and the Richie RCT reported no significant safety concerns over six months. The more serious safety signals concern injectable and cosmetic use.

• IV skin-lightening (FDA-warned): foreign and US regulators have warned that unregulated IV glutathione for skin lightening carries risks including liver, kidney, and neurological toxicity, Stevens-Johnson syndrome and other severe skin reactions, and infection transmission from unregulated products. There is no approved injectable skin-lightening product.
• Compounding contamination: the 2019 FDA action followed endotoxin-related adverse events (7 patients, including one hospitalization) linked to a specific glutathione powder used to compound sterile injectables.
• Long-term high-dose oral safety is not fully characterized.

Aesthetic use in the Spanish-speaking world — a large market, elusive evidence

Intravenous glutathione for skin lightening is a large and growing phenomenon across Latin America (and Asia, the Middle East, and Africa), heavily marketed through beauty clinics and online. For a Spanish-speaking reader this is the most likely real-world encounter with glutathione, so it deserves a plain, safety-first account.

• The evidence does not match the marketing. A widely cited dermatology review (Sonthalia et al., Indian J Dermatol Venereol Leprol 2016) finds a dichotomy between the hype and the evidence: the skin-lightening studies are small, in healthy volunteers, very short, and often do not even measure blood glutathione, and — despite rampant IV use in some countries — evidence favouring the intravenous practice "remains elusive." The authors note the depigmentary promotion "may be a marketing gimmick"; a later narrative review reaches the same cautious conclusion.
• The safety signal is real. IV glutathione for this off-label use has been linked to serious reactions (severe cutaneous eruptions, hepatic, renal, and thyroid disturbance), with no standardised dose or protocol. The Philippine FDA prohibited unapproved IV glutathione for skin-whitening (2011, reaffirmed by advisory in 2019) — the clearest regulatory action, echoed by warnings elsewhere.
• Honest read. A large market is not a large evidence base, and much of the Spanish-language literature on injectable glutathione is — appropriately — risk warning, not efficacy data. Where glutathione has more legitimate study is elsewhere (antioxidant biology, some hepatic work); the cosmetic-IV indication is the one to treat with the most caution.

Legal status

Glutathione itself is not a controlled substance. In the US, oral glutathione is a legally sold dietary supplement (DSHEA), while injectable glutathione is not FDA-approved and unregulated injectable products fall outside FDA manufacturing and purity oversight. It is not on the WADA Prohibited List as a substance, though the >100 mL/12 h IV-infusion method restriction applies to athletes in tested sport. Legality is not the same as safety or efficacy, and legal status varies by country. This section is not legal advice, and legality has not been independently assessed for your jurisdiction.

How it compares

Glutathione is frequently grouped with other redox / mitochondrial molecules discussed in longevity circles, but it differs from them in a crucial way: it actually is a peptide.

Key takeaways:

• Glutathione is the "real peptide" of this group. NAD+ is a coenzyme and methylene blue is a dye — neither is a peptide — whereas glutathione is a genuine endogenous tripeptide.
• Strong biochemistry, weak outcome data. Its antioxidant role is textbook-solid, but human proof that supplementation treats disease is thin, much like NAD+.
• Route matters. Oral supplement use has a reassuring short-term safety record; injectable and cosmetic use is where the regulatory warnings concentrate.

Common misconceptions

• "Glutathione isn't really a peptide." It is. It is a genuine endogenous thiol tripeptide (gamma-glutamyl-cysteinyl-glycine) — unlike NAD+ (a coenzyme) or methylene blue (a dye), which are cataloged here only because they are discussed alongside peptides.
• "Oral glutathione can't be absorbed at all." Standard oral GSH has historically poor bioavailability due to GI degradation, but a 6-month RCT still showed it raised body stores, and micellar/liposomal forms report higher blood exposure. "Poor" is not "zero."
• "Raising glutathione treats disease." Supplementation can raise levels and surrogate markers, but hard clinical outcome benefit in humans is largely unproven.
• "IV glutathione is an approved skin-lightening treatment." No. There is no FDA-approved injectable skin-lightening product, and the FDA and foreign regulators have warned against IV glutathione for this use.
• "It's banned in sport." Glutathione is not a WADA-prohibited substance. Only large-volume IV infusion (>100 mL/12 h) is restricted, as a method, regardless of substance.